JY
ADCT icon

Jeff Yass’s ADC Therapeutics ADCT Stock Holding History

Jeff Yass’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,800
Closed -$195K – 12200
2025
Q3 		$195K Sell
48,800
-8,200
-14% -$25.8K ﹤0.01% 11020
2025
Q2 		$153K Buy
+57,000
New +$120K ﹤0.01% 11484
2025
Q1 		– Sell
-28,900
Closed -$57.5K – 12378
2024
Q4 		$57.5K Buy
+28,900
New +$75.6K ﹤0.01% 11621
2024
Q3 		– Sell
-30,800
Closed -$97.3K – 11861
2024
Q2 		$97.3K Buy
30,800
+2,000
+7% +$7.95K ﹤0.01% 11044
2024
Q1 		$129K Buy
+28,800
New +$106K ﹤0.01% 11036
2022
Q4 		– Sell
-29,500
Closed -$142K – 12269
2022
Q3 		$142K Buy
+29,500
New +$214K ﹤0.01% 11313
2022
Q1 		– Sell
-51,100
Closed -$1.03M – 12883
2021
Q4 		$1.03M Buy
51,100
+1,900
+4% +$45.8K ﹤0.01% 7211
2021
Q3 		$1.34M Sell
49,200
-2,300
-4% -$58.9K ﹤0.01% 6795
2021
Q2 		$1.25M Sell
51,500
-19,000
-27% -$441K ﹤0.01% 7125
2021
Q1 		$1.72M Buy
70,500
+51,400
+269% +$1.49M ﹤0.01% 6283
2020
Q4 		$611K Buy
19,100
+8,900
+87% +$292K ﹤0.01% 7847
2020
Q3 		$336K Buy
+10,200
New +$441K ﹤0.01% 8473

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's ADCT Position: Q2 2026 in Review

Jeff Yass sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 76,268 shares — an estimated $286K sold.

Jeff Yass first reported a position in ADCT in Q4 2020 and held it in 15 quarters. The position peaked at $2.42M in Q1 2021. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jeff Yass reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 76,268 ADC Therapeutics shares in Q2 2026, an estimated $286K.
  • Jeff Yass first reported a position in ADC Therapeutics in Q4 2020 and held it in 15 quarters.
  • Jeff Yass's ADC Therapeutics position peaked at $2.42M in Q1 2021.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.